- Imperial College of London review suggests that cannabis-based medicinal products offer significant relief from intractable epilepsy
- CNSC produces proprietary CBD products under the Xceptol brand that are created with branded Technology CiBiDinol that increases absorbability, bioavailability, shelf life
- Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products
Researchers from the Imperial College of London recently conducted a review that examined the impact of cannabis-based medicinal products containing cannabidiol (“CBD”) on the frequency of epileptic seizures and determined that they offer patients significant relief from intractable epilepsy (https://cnw.fm/XL0hJ). As scientific evidence supporting the use of CBD becomes mainstream, concerns about absorbability, shelf life and bioavailability continue to mount. CannAssist International (OTCQB: CNSC) is dedicated to addressing these problems through the creation of CBD products using their branded technology CiBiDinol specifically created to overcome these critical issues. Marketed under the Xceptol consumer brand, CNSC’s line of products promise increased efficacy, absorption and bioavailability for superior results and efficiency per dose.
Treating epilepsy using CBD is not a new phenomenon. One of the best-known cases dates back to 2012 and concerns Charlotte Figi, a little girl who suffered up to 300 grand mal seizures per week that kept her confined to a wheelchair. The use of CBD oil to treat her condition reduced the number of seizures to 2-3 per month and sparked the medical marijuana movement that catalyzed the lifting of prohibitions on cannabis-based products throughout the…
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://cnw.fm/CNSC
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.